RxDoctor Payments Data

Taryn Digiacomo

Nurse Practitioner · Middletown, CTNPI 1568127835

Payments from drug & device makers

$609in general payments, 2019–2025

Across 15 payments — averaging $40.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$199
  • Bristol Myers Squibb$137
  • AbbVie$132
  • E.r. Squibb & Sons, L.L.C.$35
  • AstraZeneca$31
  • Daiichi Sankyo Inc.$23
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$41067%
  • Education$19933%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$609 in reported general payments places this provider in the 80th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$149,077
Medicare patients
87
Services billed
10,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide22$409,888
Lenalidomide29$391,960
CalquenceAcalabrutinib Maleate15$230,609
SprycelDasatinib12$217,977
VenclextaVenetoclax12$142,716
GleevecImatinib Mesylate12$79,060
XareltoRivaroxaban19$20,236
Abiraterone Acetate18$13,146
EliquisApixaban13$12,230
Dexamethasone52$720
Prochlorperazine Maleate66$700
Anastrozole43$674
Ondansetron Hcl40$541
Hydroxyurea27$532
Tamoxifen Citrate22$497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$137$409,88822 claims
AstraZenecaCalquence$31$230,60915 claims
E.r. Squibb & Sons, L.L.C.Sprycel$35$217,97712 claims
AbbVieVenclexta$132$142,71612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →